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Introduction
Central nervous system (CNS) involvement has been
reported to occur in 14–75% of all systemic lupus erythe-
matosus (SLE) patients [1–3]. The large differences
regarding the frequency depend on the diagnostic criteria
applied. CNS lupus can occur at any time during the
course of SLE and its symptoms are extremely diverse.
The features of this condition may include seizures, stroke,
depression, psychoses and disordered mentation. Dementia,
a common state in the population in general, is occasion-
ally also reported in SLE patients [4]. Neuropsychiatric
involvement in SLE (NPSLE) has been shown to predict a
high frequency of flares and is considered a major cause
of longstanding functional impairment as well as a cause
of mortality [5]. CNS lupus in recent decades has been
treated with cytotoxic drugs that improve the disease
outcome [6,7]. However, acquisition of valuable treatment
remedies increases the need for early recognition of CNS
AD = Alzheimer disease; Aβ42 = β-amyloid protein; APP = amyloid precursor protein; CNS = central nervous system; CSF = cerebrospinal fluid;
ELISA = enzyme-linked immunosorbent assay; IL = interleukin; MRI = magnetic resonance imaging; NPSLE = neuropsychiatric systemic lupus
erythematosus; SLE = systemic lupus erythematosus; TGF-β = transforming growth factor beta.
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Abstract
Symptoms originating from the central nervous system (CNS)
frequently occur in patients with systemic lupus erythematosus
(SLE). These symptoms are extremely diverse, including a state
of dementia. The aim of this study was to examine the
cerebrospinal fluid (CSF) content of soluble molecules
indicating axonal degeneration and amyloidogenesis.
One hundred and fourteen patients with SLE and age-matched
controls were evaluated clinically, with magnetic resonance
imaging of the brain and CSF analyses. Levels of tau, amyloid
precursor protein (APP), β-amyloid protein (Aβ42), and
transforming growth factor beta (TGF-β) were all determined
using sandwich ELISAs.
APP and Aβ42 levels were significantly decreased in SLE
patients irrespective of their CNS involvement, as compared
with healthy controls. Patients with neuropsychiatric SLE who
underwent a second lumbar puncture following successful
cyclophosphamide treatment showed further decreases of
Aβ42. CSF-tau levels were significantly increased in SLE
patients showing magnetic resonance imaging-verified brain
pathology as compared with SLE patients without such
engagement. Importantly, tau levels displayed significant
correlation to Aβ42 levels in the CSF. Finally, TGF-β levels
were significantly increased in patients with neuropsychiatric
SLE as compared with those without.
Low intrathecal levels of Aβ42 found in SLE patients seem to
be a direct consequence of a diminished production of APP,
probably mediated by heavy anti-inflammatory/immuno-
suppressive therapy. Furthermore, our findings suggest that
CSF tau can be used as a biochemical marker for neuronal
degeneration in SLE. Finally, the increased TGF-β levels
observed may support a notion of an ongoing anti-
inflammatory response counteracting tissue injury caused by
CNS lupus.
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manifestations in lupus and continuing evaluation of local
(i.e. intrathecal) responses to the medication.
Due to the multiple pathogenic mechanisms causing mani-
festations of CNS lupus, there is no single confirmatory
diagnostic test available. Several clinical, laboratory, and
radiographic test findings are reported to be abnormal in
some but not all patients with CNS lupus. Magnetic reso-
nance imaging (MRI) of the brain has been shown valuable
in detecting even minor lesions caused by CNS lupus and
correlated to CNS manifestations in SLE [8]. Pleocytosis
and elevated protein levels are found in some but not all
patients with CNS lupus [9,10]. Elevated concentrations
of IgG in the cerebrospinal fluid (CSF), of the
IgG–albumin ratio and of the IgG index, and the presence
of oligoclonal bands have all been described with varying
frequencies in patients with NPSLE [11–13]. A few
studies have demonstrated elevated IL-6 levels in the CSF
from patients with CNS lupus [14–18]. Some other
reports have described increased levels of IL-1 [14], of
IL-8 [16] and of interferon gamma [19] in CSF from
patients with CNS lupus. All these biochemical indices are
indirect measures of brain inflammation. In contrast to a mul-
titude of studies analyzing local inflammatory response in
NPSLE, the evaluation of neuronal damage and the forma-
tion of toxic metabolic products such as β-amyloid protein
(Aβ42) have not been assessed at all in this condition.
Protein tau is a microtubuli-associated protein that pro-
motes assembly and stability of microtubuli [20]. Elevated
CSF-tau levels are found in neurodegenerative disorders
such as Alzheimer disease (AD) and in acute CNS disor-
ders such as stroke [21], and they reflect neuronal and
axonal degeneration and damage. In contrast, decreased
CSF-Aβ42 levels reflect either increased deposition of this
molecule in senile plaques and cerebral blood vessels
(e.g. commonly occurring in AD) and/or decreased syn-
thesis of β-amyloid precursor protein (APP) [22], a large
transmembrane protein. Numerous studies have found
increased CSF-tau levels, decreased CSF-Aβ42 levels
but variable levels of CSF-APP in AD [22–25].
Transforming growth factor beta (TGF-β), produced by
both glial cells and neuronal cells within the brain [26], is a
multifunctional cytokine of importance in many physiologi-
cal processes, including vascular development, immune
responses and fibrosis [27–29]. TGF-β in AD is present at
increased levels in the CSF [30], and has also been
detected in senile plaques.
The aim of the present study was to measure the levels of
brain-specific proteins directly or indirectly related to
dementia disorders (tau, Aβ42, APP and TGF-β) in the
CSF of SLE patients with and without CNS involvement,
and to assess these data prospectively with respect to
immunosuppressive treatment. Our results indicate that
the SLE patients studied display significantly decreased
levels of Aβ42 and APP, irrespective of their CNS
engagement. Prospective evaluation of a subgroup of
these patients indicates that combined anti-inflammatory/
immunosuppressive treatment further downregulated
expression of these molecules. Despite this clear down-
regulation of Aβ42, none of the SLE patients included in
the study fulfilled the criteria of dementia of any type.
Materials and methods
Participants
One hundred and fourteen patients fulfilled four or more of
the American Rheumatism Association 1987 updated
revised criteria for the classification of SLE [31]. The 96
females and 18 males, 17–75 years old (mean age ± stan-
dard deviation, 40 ± 13 years), were all patients at the
Departments of Rheumatology at Sahlgrenska University
Hospital or at Karolinska University Hospital. The patients
were consecutively incorporated into the study. The
patients underwent a thorough clinical examination by an
experienced staff rheumatologist, neurologist and neu-
ropsychologist. Examination of the CNS signs and symp-
toms included lumbar puncture, neuropsychological tests
and MRI of the brain. Nine of the patients underwent
lumbar puncture twice, four patients on three occasions
and one patient on four occasions.
The proposed definition for CNS lupus in the American
Rheumatism Association’s criteria for SLE [31] appears
inadequate, given that only two elements (psychosis and
seizures) are included. As previously described [32], we
defined CNS lupus as the presence of at least two of the
following seven items occurring in association with clinical
evidence of disease progression: recent onset psychosis,
transverse myelitis, aseptic meningitis, seizures, pathologi-
cal brain MRI, severely abnormal neuropsychiatric test
[33] or oligoclonal IgG bands in the CSF. The pathogen-
esis of antiphospholipid antibody-mediated brain damage
is a thrombotic complication rather than an inflammatory
complication of SLE, so we decided to exclude this condi-
tion from the definition of CNS lupus. Non-SLE causes of
neurological events (e.g. cerebral infections) were also
ruled out. Based on the earlier criteria, the patients were
divided into three distinct groups: group I, patients with
CNS lupus (n = 36); group II, patients with SLE but
without any signs of CNS engagement (n = 71); and
group III, patients with SLE complicated by antiphospho-
lipid syndrome (n = 7). The exact frequency of various
CNS manifestations and the patient treatment found in our
population of SLE patients are presented in Tables 1 and
2. The study was approved by the ethical committee of the
University of Göteborg.
Control subjects
Forty-one females and 12 males, without a previous
history of neurological disorder and with a normal neuro-R131
logical status, served as controls in the present study.
CSF-tau levels and CSF-Aβ42 levels from the 53 patients,
and CSF-APP levels from 35 of these 53 healthy subjects
(mean age ± standard deviation, 42 ± 17 years), were
measured. There were no significant differences between
males and females with respect to intrathecal levels of
either  tau (179 ± 121 pg/ml versus 151 ± 98 pg/ml,
not significant), Aβ42 (828 ± 190 pg/ml versus
842 ± 173 pg/ml,  P = 0.8), or APP (7178 ± 866 pg/ml
versus 6644 ± 1318 pg/ml, not significant).
CSF analyses
Levels of tau were determined using a sandwich ELISA
(Innotest hTAU-Ag; Innogenetics, Gent, Belgium), con-
structed to measure both phosphorylated tau and non-
phosphorylated tau [34,35]. The level of Aβ42 was
determined using an ELISA (Innotest β-amyloid(1–42); Inno-
genetics) specific for Aβ42 [36,37].
The levels of total APP were determined using a novel sand-
wich ELISA (unpublished data) based on the monoclonal
antibody 22C11 (Chemicon, Temecula, CA, USA) and the
biotinylated monoclonal LN27 (Zymed, San Francisco, CA,
USA). Capturing antibody 22C11, recognizing an epitope
within amino acids 66–81 of the N-terminus of APP, was
used to coat plastic dishes, whereas LN27, which is reac-
tive to an epitope within the first 200 amino acids of APP,
was used as a detection antibody. The concentration of
APP in samples of CSF was calculated from the linear part
of a standard curve. In contrast to other analyses, only
86 SLE patients were analyzed regarding APP.
A sandwich ELISA (Amersham Pharmacia Biotech, Little
Chalfont, Buckinghamshire, UK) was used to measure
TGF-β in the CSF of 104 SLE patients. The detection
level was 4 pg/ml. All values below the detection levels
were considered negative. Paired serum and CSF
samples were analyzed for albumin and IgG levels using
nephelometry. As an indicator of blood–brain barrier func-
tion, the quotient of CSF albumin × 103/serum albumin
was analyzed (normal values: <6.8, younger than 45 years
of age; <10.2, older than 45 years of age) [38]. The
CSF/serum IgG index was used as a measure of intrathe-
cal IgG production and calculated using the formula:
IgG index = CSF – IgG (mg/l) / S – IgG (g/l)
CSF – albumin (mg/l) / S – albumin (g/l)
(normal value <0.7). All CSF samples were also analyzed
by isoelectric focusing to permit detection of oligoclonal
IgG bands. These bands represent the brain-infiltrating
oligoclonal B-cell population.
MRI analyses
Neuroimaging was performed to evaluate the extent and
localization of brain lesions. The neuroimaging technique
Available online http://arthritis-research.com/content/6/2/R129
Table 1
Pharmacological treatment of patients with systemic lupus erythematosus included in the study, at the time the lumbar puncture
was performed
NPSLE No NPSLE Antiphospholipid
Treatment (n = 36) (n = 71) antibody syndrome (n = 7)
Prednisolone (≤ 10 mg) 15 (42%) 39 (55%) 1 (14%)
Prednisolone (> 10 mg) 3 (8%) 13 (18%) 0 (0%)
No prednisolone 16 (58%) 21 (30%) 5 (29%)
Antimalarials 3 (8%) 7 (10%) 0 (0%)
Azathioprine 2 (6%) 8 (11%) 2 (29%)
Azathioprine+ cyclosporin A 2 (6%) 2 (3%) 0 (0%)
Methotrexate 2 (6%) 1 (1.5%) 0 (0%)
Cyclosporin A 1 (3%) 6 (8%) 1 (14%)
Cyclophosphamide 11 (31%) 11 (15%) 0 (0%)
Cyclophosphamide+ cyclosporin A 3 (8%) 1 (1.5%) 0 (0%)
Cyclophosphamide+antimalarials 1 (3%) 1 (1.5%) 0 (0%)
No cytotoxic drug 11 (31%) 34 (48%) 4 (57%)
Antihypertensive treatment 12 (33%) 18 (25%) 1 (14%)
Low-dose aspirin 7 (19%) 17 (24%) 3 (43%)
Warfarin 3 (8%) 0 (0%) 2 (29%)
NPSLE, neuropsychiatric systemic lupus erythematosus.used was multiplanar MRI. The MRI examinations (Philips
Gyroscan NT5, Einhoven, The Netherlands) were per-
formed with axial proton density and T2-weighted images
of the brain. The following findings were considered to be
pathological: myelitis, brain atrophy leading to expansion
of the ventricles, multiple high signal changes in the white
matter, multiple sclerosis-like changes and infarctions. MRI
abnormalities were seen in 67% of cases with CNS lupus
and in 30% of SLE cases classified as cerebrally healthy.
Neuropsychological assessment
The neuropsychiatric tests were carried out by a profes-
sional neuropsychologist and judged as pathological or
not. The test battery included neuropsychological
assessment of the following categories: memory and
learning, attention, psychomotor speed, and visiospatial
ability. If at least one of the categories was pathological,
the patient tested was found to have an abnormal neuro-
psychiatric test. Results regarding MRI and neuro-
psychological assessment were not accessible for the
respective investigators.
Statistical analysis
Statistical comparisons were made using the nonparamet-
ric Mann–Whitney U test, or the Wilcoxon’s test for paired
data in the case of follow-up data. Results are presented
as means ± standard error of the mean. P ≤ 0.05 was con-
sidered statistically significant. Spearman rank correlation
was used for calculation of correlations. The statistical
analyses were carried out using the Statview® program.
Results
One hundred and fourteen patients met the inclusion crite-
ria for SLE diagnosis. Thirty-six patients were found to
have NPSLE in accordance with the criteria presented in
Materials and methods, seven patients were found to have
phospholipid antibody syndrome and the remaining
71 SLE patients were considered cerebrally healthy.
Mild pleocytosis was seen in patients with CNS lupus
( 1 0×1 0 6 ±7×1 0 6 cells/l) compared with cerebrally
healthy SLE patients (2 × 106 ± 0.5 × 106 cells/l) (not sig-
nificant). As previously validated [39], we found an
increased number of oligoclonal bands in the CSF of the
CNS lupus group (2.2 ± 0.4) as compared with SLE
patients without CNS involvement (0.4 ± 0.2)
(P ≤ 0.0005). The mean level of the CSF/serum albumin
ratio was not increased in patients with NPSLE
(5.5 ± 0.4 mg/dl) as compared with cerebrally healthy SLE
subjects (5.2 ± 0.4 mg/dl) (not significant). There were no
significant differences regarding levels of serum antibod-
ies specific for native DNA, or regarding complement
levels (C3 and C4) between SLE patients with or without
CNS involvement.
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Table 2
Clinical central nervous system (CNS) manifestations in systemic lupus erythematosus patients included in the study
NPSLE No NPSLE Antiphospholipid
CNS manifestations (n = 36) (n = 71) antibody syndrome (n = 7)
Acute confusional state 2 (6%) 1 (1.5%) 0 (0%)
Anxiety disorder 1 (3%) 5 (7%) 0 (0%)
Aseptic meningitis 1 (3%) 0 (0%) 0 (0%)
Cerebrovascular disease 5 (14%) 7 (10%) 4 (57%)
Cognitive dysfunction 7 (19%) 19 (27%) 0 (0%)
Demyelinating syndrome 3 (8%) 1 (1.5%) 0 (0%)
Headache 8 (22%) 28 (39%) 3 (43%)
Mood disorders 7 (19%) 10 (14%) 1 (14%)
Movement disorder 2 (6%) 0 (0%) 0 (0%)
Myastenia gravis 0 (0%) 2 (3%) 0 (0%)
Myelopathy 2 (6%) 0 (0%) 0 (0%)
Polyneuropathy 0 (%) 2 (3%) 0 (0%)
Mononeuropathy 0 (0%) 1 (1.5%) 0 (0%)
Neuropathy 0 (0%) 2 (3%) 1 (14%)
Psychosis 2 (6%) 1 (1.5%) 0 (0%)
Seizure disorders 6 (17%) 0 (0%) 0 (0%)
Each patient may have had multiple clinical manifestations of the CNS involvement. NPSLE, neuropsychiatric systemic lupus erythematosus.Intrathecal Aβ42 levels were decreased in all the SLE
patients compared with healthy controls (mean ± standard
error of the mean, 574 ± 17 pg/ml versus 831 ± 25 pg/ml;
P < 0.0001) (Fig. 1a). Patients with NPSLE had slightly
but not significantly decreased Aβ42 levels as compared
with patients without CNS lupus (541 ± 34 pg/ml versus
583 ± 18 pg/ml, not significant).
A second lumbar puncture was performed in nine patients
who met the criteria of NPSLE and were successfully
treated with cyclophosphamide. The CSF levels of Aβ42
were further decreased on the second occasion as com-
pared with the first (702 ± 45 pg/ml versus
621 ± 45 pg/ml, P ≤ 0.05). In contrast, CSF levels of tau
were not affected by treatment (275 ± 77 pg/ml versus
273 ± 61 pg/ml, not significant). To investigate whether
the decreased Aβ42 levels in SLE patients are due to a
diminished production or to its local deposition in the
brain, we analyzed the intrathecal levels of APP. We found
decreased CSF-APP levels (Fig. 1b) in SLE patients com-
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Figure 1
Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein but increases of intrathecal axonal degradation products and TGF-β
in patients with cerebral lupus. (a) Cerebrospinal fluid (CSF) content of soluble amyloid β-protein (Aβ42) in patients with systemic lupus
erythematosus (SLE) with and without central nervous system (CNS) engagement, as well as in cerebrally healthy control subjects. (b) CSF
content of amyloid precursor protein (APP) in patients with SLE with and without CNS engagement, as well as in cerebrally healthy control
subjects. (c) CSF content of tau in patients with SLE stratified with respect to brain magnetic resonance imaging (MRI)-verifiable changes, and in
cerebrally healthy control subjects. (d) CSF content of transforming growth factor beta (TGF-β) in SLE patients stratified with respect to the
presence/absence and type of CNS engagement. NPSLE, neuropsychiatric systemic lupus erythematosus.pared with healthy controls (4834 ± 314 pg/nl versus
7010 ± 714 pg/nl,  P < 0.001), clearly indicating
decreased production of this precursor molecule.
There were no statistically significant differences regarding
CSF-tau levels between healthy controls and patients with
NPSLE (173 ± 16 pg/ml versus 237 ± 35 pg/ml).
However, upon stratification of all the SLE patients into
two groups, according to the presence or absence of MRI
findings, we found a statistical difference regarding
CSF-tau levels in SLE patients with MRI pathology com-
pared with those without (261 ± 26 pg/ml versus
164 ± 15 pg/ml,  P < 0.01) (Fig. 1c). Next we assessed
the possible relationship between decreased Aβ42 and
increased tau levels in the whole patient population. Our
results show clearly that these two molecules, related to
neuronal toxicity and damage, display a significant relation-
ship (r = 0.48, P < 0.0001).
We finally decided to assess CSF levels of TGF-β,
another amyloidogenic protein with anti-inflammatory
properties. In the CNS lupus group, intrathecal levels of
TGF-β were significantly increased compared with those
of SLE patients without overt CNS disease (mean ± stan-
dard error of the mean, 54.3 ± 8.4 pg/ml versus
31.6 ± 4.8 pg/ml; P ≤ 0.01), as seen in Fig. 1d.
Discussion
Patients with SLE present with a wide array of neuropsy-
chiatric features, although evidence for dementia in these
patients is scarce.
The precise pathogenic mechanisms of neuropsychiatric
manifestations are still the subject of intense investiga-
tions, but autoantibody and cytokine-mediated neural dys-
function, intracranial angiopathy and coagulopathy have all
been implicated. Although there is no diagnostic golden
standard for CNS lupus, there is a wide selection of non-
invasive tests that are of value in the assessment and mon-
itoring of the individual patients. Autopsy studies of brains
from SLE patients have revealed vasculopathy [40] as a
pathogenic event either directly responsible for clinical
neuropsychiatric events or, alternatively, by altering
blood–brain barrier permeability and facilitating the access
of pathogenic antibodies from the circulation into an
immunologically privileged site that is normally protected
from aberrant immune responses. The extracellular fluid of
the brain is in direct contact with the CSF, and biochemi-
cal processes in the brain can be reflected therein. Analy-
sis of degradation products from neuronal cells found in
CSF would be of value to improve the clinical evaluation of
NPSLE and to study the ongoing brain parenchyme status
in living subjects with NPSLE.
In the current study, we found significantly decreased
levels of Aβ42 in the CSF of SLE patients compared with
healthy control subjects. Low levels of CSF-Aβ42 may be
either due to their accumulation and deposition (e.g. as
diffuse plaques, as in the case of AD) and/or to a
decreased production of APP by neuronal cells. Our
results showed significantly decreased levels of APP in
SLE patients included in the study compared with neuro-
logically healthy subjects, indicating decreased production
rather than increased tissue deposition. What would be
the cause of the decreased APP production in SLE
patients? At first glance, there were no differences in the
CSF-APP levels with respect to the medication (corticos-
teroids, immunosuppressive drugs). However, the variabil-
ity of the patient material as well as differences in duration
and intensity of the treatment throw doubt on this conclu-
sion. Interestingly, a subpopulation of nine patients was
followed prospectively after immunosuppressive treat-
ment. In this group such a treatment resulted in signifi-
cantly decreased Aβ42 levels. This finding indicates that
treatment with alkylating agents such as cyclophosphamide
might affect either the production of APP or the activity of
secretases. Indeed, it has been recently demonstrated that
anti-inflammatory drugs may directly modulate γ-secretase
activity and thereby decrease Aβ42 production [41].
We showed that SLE patients with MRI findings compared
with those without MRI findings had significantly higher
CSF-tau levels. These increases reflect the neuronal
damage of the brain in SLE patients. Indeed, our recent
study [32] supports this conclusion since another neuronal
protein, neurofilament protein, was also increased.
Importantly, a significant relationship was noted between
the occurrence of tau and of Aβ42. This finding, together
with the correlation between tau and MRI-verified brain
damage, indicates that Aβ42 might have exerted its toxic-
ity locally, leading to sequels. Finally, as previously found
in AD [30] and in low-pressure hydrocephalus-induced
dementia (unpublished observation), levels of TGF-β in the
CSF of NPSLE patients were clearly increased. Such an
increase may be very well related to the disease process
itself since, at least in the case of patients with low-pres-
sure hydrocephalus, a shunt operation will simultaneously
lead to decreased levels of TGF-β and increased menta-
tion (unpublished observation).
Altogether, our results show that there is increased pro-
duction of TGF-β and an ongoing destruction of brain
parenchyma (manifested as increased tau levels) in the
brains of SLE patients. We suggest that levels of toxic
Aβ42 and its precursor APP reflect efficient cytotoxic
therapy, as shown in a limited subgroup analysis.
Notably, while our findings shed some light on the
pathogenesis of cerebral lupus, none of the findings
reported in the present study may be used as a diag-
nostic parameter, since many other brain diseases show
similar patterns.
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Our findings indicate that intrathecal levels of tau, a
marker of neuronal degeneration, are clearly increased in
SLE patients with MRI-verifiable brain lesions, both as
compared with CSF findings of healthy controls as well as
of lupus patients without MRI-verified brain pathology. This
finding, together with increased intrathecal levels of
TGF-β, indicates an ongoing destructive parenchymatous
process in the SLE brain.
In addition, the present study provides evidence of
decreased intrathecal levels of Aβ42 in SLE patients irre-
spective of CNS engagement. We interpret this finding
not as a sign of early dementia, but rather as a sign of
decreased APP synthesis, a precursor of Aβ42, as verified
in the present study. We suggest that this decrease may
be an outcome of an intense immunosuppressive treat-
ment to which the majority of SLE patients included in the
study are being subjected.
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